Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 43.01% | -27.03% | 28.76% | -26.63% | 94.88% |
| Total Depreciation and Amortization | 77.42% | 239.73% | -2.67% | -2.60% | 5.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 163.85% | 183.87% | -152.22% | -44.76% | 643.35% |
| Change in Net Operating Assets | 124.84% | -2,570.00% | -102.52% | 164.36% | -373.66% |
| Cash from Operations | 189.74% | -6.45% | -62.46% | 70.73% | 123.04% |
| Capital Expenditure | -48.72% | 14.29% | -479.17% | 118.18% | -5.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -99.98% | 498.16% | -913.20% | 69.86% | -1,012.12% |
| Cash from Investing | 91.80% | 73.25% | -856.90% | 73.11% | -578.28% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -70.17% | 259.32% | -36.73% | -18.20% | 216.67% |
| Repurchase of Common Stock | -582.31% | 86.60% | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -218.30% | 173.64% | -330.83% | -18.20% | 1,481.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 379.97% | 114.42% | -219.77% | 389.24% | 9.01% |